Category Archives: Health

4 OTC Medications You’re Probably Taking Too Much Of — Best Life

If you frequently use over-the-counter (OTC) medications, you’re among the more than 260 million Americans who report using them regularly. According to Pharmacy Times, 9 out of 10 Americans rely on these staple household products to help address various ailments, including aches and pains, fever, cold symptoms, and allergies. While OTC medications can be a lifesaver and help you get back up on your feet after a cold or flu has wiped you out, taking too many of these drugs can be hazardous for your health.

“OTC medicines are generally safe, but problems can occur if someone is taking them while on prescription medications,” says Laura Purdy, MD, MBA, a board-certified family physician in Fort Benning, Georgia. Read on to find out which popular medications you might be taking too much of and what you should do instead.

READ THIS NEXT: 5 Things You Need to Take Out of Your Medicine Cabinet Now, Pharmacists Say.

Jeffrey Budde/Shutterstock

You’re unlikely to find someone who hasn’t taken acetaminophen at some point in their life. Acetaminophen is the active ingredient in Tylenol and one of North America’s most commonly used pain relief medications. This drug offers myriad benefits, such as reducing fevers and providing pain relief from toothaches, headaches, arthritis, and more.

While Tylenol is great when you need it, adults shouldn’t take more than 3,000 milligrams of acetaminophen in a single day (this amount is even less if you’re over 65). The National Institutes of Health (NIH) states that exceeding 7,000 milligrams or more can have serious health consequences and lead to overdose. In addition, high doses of acetaminophen can damage the liver and even result in a liver transplant or death.

It’s common to assume that you don’t need to worry about overdosing if a product is sold without a prescription. Unfortunately, that’s not the case. “Even with a drug or supplement facts panel on the back of the box, oftentimes consumers are unaware that a single ingredient is duplicated across multiple products,” says Brandi Cole, PharmD, pharmacist and nutritionist at Persona Nutrition. “These duplications can quickly add up to a higher daily dosage than a consumer may have intended, resulting in bothersome side effects and some rare cases toxicity.”

READ THIS NEXT: This Popular OTC Drug Can Easily Cause “Severe Damage,” Doctor Warns.

The Image Party/Shutterstock

The U.S. Food and Drug Administration (FDA) has cautioned against taking higher than the recommended dose of the widely used OTC allergy medication diphenhydramine (the active ingredient in Benadryl). Too much diphenhydramine can lead to severe health consequences like heart problems, seizures, coma, and death. According to the NIH, diphenhydramine is an antihistamine used to relieve allergy symptoms, including rashes, itching, watery eyes, irritated sinuses, cough, runny nose, and sneezing. People also use diphenhydramine to prevent and treat motion sickness symptoms.

“Diphenhydramine appears in several OTC products not labeled for allergy use, including temporary sleep aids and just about anything in the cold and flu aisle marked PM,” says Cole. “[Since] it appears in unexpected places, it’s possible to take too much—even when you’re following the guidelines on each of your medications.”

If you regularly exceed the recommended dose of 200 to 300 milligrams a day, you may encounter undesirable side effects, reports Everyday Health. These include severe drowsiness, vomiting, confusion, ringing in the ears, blurred vision, rapid heart rate, hallucinations, and seizures. “To be safe, always check the active ingredients when choosing a new product or ask your pharmacist about using a specific combination,” recommends Cole.

calimedia/Shutterstock

Americans are no strangers to caffeine. In fact, 85 percent of the U.S. population drinks at least one caffeinated beverage daily. But did you know caffeine is found in many OTC headache medications and weight loss supplements? So if you enjoy a few cups of java in the morning but regularly take headache medications such as Excedrin, Anacin, or Midol, you could be well above caffeine’s recommended daily intake of 400 milligrams per day.

“Each person responds differently to caffeine, but generally speaking, moderation is a good idea,” advises Cole. “Those sensitive to its effects could experience jitteriness, nervousness, or irritability—even with marginally increased intake. In very high doses, it can cause severe anxiety, changes in heartbeat, or dehydration.”

For more health news sent directly to your inbox, sign up for our daily newsletter.

MIA Studio/Shutterstock

Iron is an essential nutrient, meaning we need to obtain it through food or supplements. Since iron plays a critical role in red blood cell production, it’s commonly found in multivitamins and supplements that promote blood and heart health. The amount of iron we need daily varies depending on age and gender. However, if you eat lots of high-iron foods and take iron-containing supplements, you could be at risk of iron toxicity.

“Consuming more than the recommended amount of iron can lead to uncomfortable GI side effects, like abdominal pain and constipation. Frequent use of large doses could even damage the lining of the stomach,” Cole warns. “These adverse effects are most common when taking up to 45 milligrams daily from diet and supplement sources.” Before starting an iron supplement, talk to your doctor or a pharmacist—especially if you eat high-iron foods like red meat, lentils, or dark, leafy greens.

Best Life offers the most up-to-date information from top experts, new research, and health agencies, but our content is not meant to be a substitute for professional guidance. When it comes to the medication you’re taking or any other health questions you have, always consult your healthcare provider directly.

Read original article here

Latest Covid Boosters Are Set to Roll Out Before Human Testing Is Completed

The Food and Drug Administration is expected to authorize new Covid-19 booster shots this week without a staple of its normal decision-making process: data from a study showing whether the shots were safe and worked in humans.

Instead, the agency plans to assess the shots using data from other sources such as research in mice, the profiles of the original vaccines and the performance of earlier iterations of boosters targeting older forms of Omicron.

“Real world evidence from the current mRNA Covid-19 vaccines, which have been administered to millions of individuals, show us that the vaccines are safe,” FDA Commissioner

Robert Califf

said in a recent tweet. The FDA pointed to Dr. Califf’s tweets when asked for comment.

Clearance of the doses, without data from human testing known as clinical trials, is similar to the approach the FDA takes with flu shots, which are updated annually to keep up with mutating flu viruses.

Some vaccine experts have urged the agency to wait before clearing the new Covid-19 booster doses.



Photo:

EMILY ELCONIN/REUTERS

The approach has raised concerns, however, among some vaccine experts who have urged the agency to wait.

“I’m uncomfortable that we would move forward—that we would give millions or tens of millions of doses to people—based on mouse data,” said

Paul Offit,

an FDA adviser and director of the Vaccine Education Center at Children’s Hospital of Philadelphia.

The comparison with flu vaccines isn’t sound, Dr. Offit said, because flu viruses mutate so rapidly that shots from one year don’t offer protection for the next, while currently available Covid-19 shots continue to keep people out of the hospital.

In addition to evaluating the boosters without clinical-trial data, the FDA won’t convene another element from its earlier Covid-19 vaccine reviews: a meeting of advisers who make recommendations whether the agency should authorize a shot.

Retooled Covid-19 boosters are similar to the original shots, including Moderna’s Covid-19 vaccines, seen last year, but have been customized to fight the latest variants.



Photo:

andrew caballero-reynolds/Agence France-Presse/Getty Images

The FDA scrapped the meeting, Dr. Califf said in his tweets on the subject, because the committee discussed the matter in June, and the agency doesn’t have new questions warranting its input.

The Covid-19 vaccines available in the U.S., which were first authorized for use in December 2020, haven’t been modified until now, though the virus they were designed to target has evolved.

The shots held up well against earlier strains, researchers found, but weren’t as effective against the newest Omicron subvariants like BA.5.

In planning for a fall booster campaign, federal health authorities in late June directed

Pfizer Inc.

and its partner

BioNTech SE,

and

Moderna Inc.

to update their shots to target BA.5, an Omicron subvariant called BA.4 and the original strain of the virus.

“We’ve validated the process several times over and continue to produce safe and effective vaccines against Covid-19,” a Pfizer spokeswoman said. Moderna said all current data indicates its shots are safe and effective.

SHARE YOUR THOUGHTS

What decisions are you making around boosters for Covid-19? Join the conversation below.

Human trials for Moderna’s vaccine targeting the subvariants have started, and for the Pfizer-BioNTech vaccine are expected to start this month, the companies have said. Results won’t be available, however, before the U.S. government’s planned fall booster campaign.

“If we waited for clinical-trial results, thank you very much, we’d get them in the spring. It takes time to do clinical trials,” said

William Schaffner,

professor of medicine at Vanderbilt University Medical Center and a nonvoting liaison to the Centers for Disease Control and Prevention committee that will decide whether to recommend the shots, should the FDA sign off. “This is just an updating of the previous vaccine that we used.”

The retooled shots are similar to the original shots, but customized to fight the latest variants, much like keys that are nearly identical but have slightly different ridges and valleys, said

John Grabenstein,

director of scientific communications for Immunize.org, a nonprofit that seeks to boost immunization rates.

With each mutation, the Covid-19 virus is becoming more transmissible. WSJ’s Daniela Hernandez breaks down the science of how Covid variants are getting better at infecting and spreading. Illustration: Rami Abukalam

The similarities make it very reasonable for regulators to weigh the overwhelmingly safe track record of the original series when considering the new shots, he said.

The FDA has reviewed test results from a shot that Moderna modified to target an early version of Omicron as well as the ancestral strain of the coronavirus. The study found the shot generated a significant amount of antibodies in humans compared with the company’s currently available booster shot. That shot is now approved in the U.K.

The agency also looked at human data from Pfizer and BioNTech finding that their experimental shots, updated to target an earlier form of Omicron, also boosted antibody levels significantly. The companies have submitted one of those shots to the U.K., EU and Canada for authorization, Pfizer has said.

Such findings give the FDA confidence that the newest modified shots will also work well, said a person familiar with the agency’s deliberations.

“As we know from prior experience, strain changes can be made without affecting safety,” Dr. Califf said in a tweet.

Dr. Offit, however, said he would like to wait for clinical-trial data showing the shots are effective before asking people to take them.

“If you have some evidence that this is likely to be of value, sure,” he said. “But if you don’t have evidence, and you know that the current vaccine does offer protection against severe disease, I don’t think it’s fair to ask people to take risks.”

Write to Liz Essley Whyte at liz.whyte@wsj.com

Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8

Read original article here

Rivaroxaban in Rheumatic Heart Disease–Associated Atrial Fibrillation

Abstract

Background

Testing of factor Xa inhibitors for the prevention of cardiovascular events in patients with rheumatic heart disease–associated atrial fibrillation has been limited.

Methods

We enrolled patients with atrial fibrillation and echocardiographically documented rheumatic heart disease who had any of the following: a CHA2DS2VASc score of at least 2 (on a scale from 0 to 9, with higher scores indicating a higher risk of stroke), a mitral-valve area of no more than 2 cm2, left atrial spontaneous echo contrast, or left atrial thrombus. Patients were randomly assigned to receive standard doses of rivaroxaban or dose-adjusted vitamin K antagonist. The primary efficacy outcome was a composite of stroke, systemic embolism, myocardial infarction, or death from vascular (cardiac or noncardiac) or unknown causes. We hypothesized that rivaroxaban therapy would be noninferior to vitamin K antagonist therapy. The primary safety outcome was major bleeding according to the International Society of Thrombosis and Hemostasis.

Results

Of 4565 enrolled patients, 4531 were included in the final analysis. The mean age of the patients was 50.5 years, and 72.3% were women. Permanent discontinuation of trial medication was more common with rivaroxaban than with vitamin K antagonist therapy at all visits. In the intention-to-treat analysis, 560 patients in the rivaroxaban group and 446 in the vitamin K antagonist group had a primary-outcome event. Survival curves were nonproportional. The restricted mean survival time was 1599 days in the rivaroxaban group and 1675 days in the vitamin K antagonist group (difference, −76 days; 95% confidence interval [CI], −121 to −31; P<0.001). A higher incidence of death occurred in the rivaroxaban group than in the vitamin K antagonist group (restricted mean survival time, 1608 days vs. 1680 days; difference, −72 days; 95% CI, −117 to −28). No significant between-group difference in the rate of major bleeding was noted.

Conclusions

Among patients with rheumatic heart disease–associated atrial fibrillation, vitamin K antagonist therapy led to a lower rate of a composite of cardiovascular events or death than rivaroxaban therapy, without a higher rate of bleeding. (Funded by Bayer; INVICTUS ClinicalTrials.gov number, NCT02832544.)

Read original article here

UCSF’s Dr. Bob Wachter not ready to ditch his mask or dine indoors

As the pandemic wears on and many people become complacent, Dr. Bob Wachter, UCSF chair of medicine, says he still plans to abstain from indoor dining, and don a mask in crowded rooms.

In a lengthy tweet thread Saturday, Wachter said he’ll return to restaurants only when daily case rates fall below 5 for every 100,000 people in the region. That’s a significant drop from the national rate of 28 cases for every 100,000 people, and even from the more moderate daily case rate in San Francisco, of 19 per 100,000.

“Clearly, many will find my threshold too conservative, others too risky,” tweeted the doctor, who has cultivated a huge social media following since the onset of COVID-19, offering prodigious, data-driven threads about the disease. His posts mix public education with personal stories and opinions: Recently, Wachter compared unmasking to reckless driving.

San Francisco dropped its mask mandates months ago, but the doctor’s string of tweets Saturday said he considered many factors before setting the yardstick for his own unmasking. Chief among them: immune status, which is better for people who are boosted and particularly those boosted recently, or those who have also had COVID. He also took the virus’ contagiousness into account — and said BA.5, which surged this summer, is “the most infectious variant yet.”

Wachter estimates a 5% to 10% chance of getting COVID from moderate exposure to an infected person, say, sitting nearby on an airplane.

Drawing on UCSF’s asymptomatic test positivity rate of 2.9% — or one person testing positive in every 35 people who have no symptoms — Wachter concluded that, in a group of 10 people, at least one will have COVID, 25% of the time.

“That’s too high for me to feel comfy ditching the mask,” Wachter said.

But he ended on a hopeful note. Future variants of COVID are unlikely to be more infectious than BA.5, and “bivalent” COVID vaccine boosters will arrive this fall.

Rachel Swan is a San Francisco Chronicle staff writer. Email: rswan@sfchronicle.com Twitter: @rachelswan

Read original article here

Monkeypox Cases Drop 21 Percent, Reversing Month-Long Increase

GENEVA—The number of monkeypox cases reported globally dropped 21 percent in the last week, reversing a month-long trend of rising infections and signaling that Europe’s outbreak may be starting to decline, the World Health Organization (WHO) said Thursday.

The U.N. health agency reported 5,907 new weekly cases and said two countries, Iran and Indonesia, reported their first cases. To date, more than 45,000 monkeypox cases have been reported in 98 countries since late April.

The Americas accounted for 60 percent of cases in the past month, WHO said, while cases in Europe comprised about 38 percent.

In late July, WHO Director-General Tedros Adhanom Ghebreyesus declared monkeypox to be a global emergency, despite a lack of consensus on his expert committee.

The Africa Centers for Disease Control and Prevention said Thursday the continent had 219 new cases in the past week, a jump of 54 percent. Most were in Nigeria and Congo.

British health authorities said last week there were “early signs” the country’s monkeypox outbreak was slowing. The UK’s Health Security Agency downgraded the country’s monkeypox outbreak last month, saying there was no evidence the once-rare disease was spreading beyond men who were gay, bisexual, or had sex with other men.

Since monkeypox outbreaks in Europe and North America were identified in May, WHO and other health agencies have noted that its spread was almost exclusively in men who have sex with men.

Monkeypox has been endemic in parts of Africa for decades and experts suspect the outbreaks in Europe and North America were triggered after the disease started spreading via sex at two raves in Spain and Belgium.

WHO’s latest report said 98 percent of cases are in men and of those who reported sexual orientation, 96 percent are in men who have sex with men.

“Of all reported types of transmission, a sexual encounter was reported most commonly,” WHO said.

Among the monkeypox cases in which the HIV status of patients was known, 45 percent were infected with HIV.

WHO has recommended that men at high risk of the disease temporarily consider reducing their number of sex partners and refraining from group or anonymous sex.

Read original article here

Artificial Intelligence Model Can Detect Parkinson’s From Breathing Patterns

Summary: A newly developed artificial intelligence model can detect Parkinson’s disease by reading a person’s breathing patterns. The algorithm can also discern the severity of Parkinson’s disease and track progression over time.

Source: MIT

Parkinson’s disease is notoriously difficult to diagnose as it relies primarily on the appearance of motor symptoms such as tremors, stiffness, and slowness, but these symptoms often appear several years after the disease onset.

Now, Dina Katabi, the Thuan (1990) and Nicole Pham Professor in the Department of Electrical Engineering and Computer Science (EECS) at MIT and principal investigator at MIT Jameel Clinic, and her team have developed an artificial intelligence model that can detect Parkinson’s just from reading a person’s breathing patterns.

The tool in question is a neural network, a series of connected algorithms that mimic the way a human brain works, capable of assessing whether someone has Parkinson’s from their nocturnal breathing—i.e., breathing patterns that occur while sleeping.

The neural network, which was trained by MIT Ph.D. student Yuzhe Yang and postdoc Yuan Yuan, is also able to discern the severity of someone’s Parkinson’s disease and track the progression of their disease over time.

Yang and Yuan are co-first authors on a new paper describing the work, published today in Nature Medicine. Katabi, who is also an affiliate of the MIT Computer Science and Artificial Intelligence Laboratory and director of the Center for Wireless Networks and Mobile Computing, is the senior author.

They are joined by 12 colleagues from Rutgers University, the University of Rochester Medical Center, the Mayo Clinic, Massachusetts General Hospital, and the Boston University College of Health and Rehabilition.

Over the years, researchers have investigated the potential of detecting Parkinson’s using cerebrospinal fluid and neuroimaging, but such methods are invasive, costly, and require access to specialized medical centers, making them unsuitable for frequent testing that could otherwise provide early diagnosis or continuous tracking of disease progression.

The MIT researchers demonstrated that the artificial intelligence assessment of Parkinson’s can be done every night at home while the person is asleep and without touching their body.

To do so, the team developed a device with the appearance of a home Wi-Fi router, but instead of providing internet access, the device emits radio signals, analyzes their reflections off the surrounding environment, and extracts the subject’s breathing patterns without any bodily contact.

The breathing signal is then fed to the neural network to assess Parkinson’s in a passive manner, and there is zero effort needed from the patient and caregiver.

“A relationship between Parkinson’s and breathing was noted as early as 1817, in the work of Dr. James Parkinson. This motivated us to consider the potential of detecting the disease from one’s breathing without looking at movements,” Katabi says.

The neural network, which was trained by MIT Ph.D. student Yuzhe Yang and postdoc Yuan Yuan, is also able to discern the severity of someone’s Parkinson’s disease and track the progression of their disease over time. Image is in the public domain

“Some medical studies have shown that respiratory symptoms manifest years before motor symptoms, meaning that breathing attributes could be promising for risk assessment prior to Parkinson’s diagnosis.”

The fastest-growing neurological disease in the world, Parkinson’s is the second-most common neurological disorder, after Alzheimer’s disease. In the United States alone, it afflicts over 1 million people and has an annual economic burden of $51.9 billion. The research team’s device was tested on 7,687 individuals, including 757 Parkinson’s patients.

Katabi notes that the study has important implications for Parkinson’s drug development and clinical care. “In terms of drug development, the results can enable clinical trials with a significantly shorter duration and fewer participants, ultimately accelerating the development of new therapies.

” In terms of clinical care, the approach can help in the assessment of Parkinson’s patients in traditionally underserved communities, including those who live in rural areas and those with difficulty leaving home due to limited mobility or cognitive impairment,” she says.

“We’ve had no therapeutic breakthroughs this century, suggesting that our current approaches to evaluating new treatments is suboptimal,” says Ray Dorsey, a professor of neurology at the University of Rochester and Parkinson’s specialist who co-authored the paper. Dorsey adds that the study is likely one of the largest sleep studies ever conducted on Parkinson’s.

“We have very limited information about manifestations of the disease in their natural environment and [Katabi’s] device allows you to get objective, real-world assessments of how people are doing at home.

“The analogy I like to draw [of current Parkinson’s assessments] is a street lamp at night, and what we see from the street lamp is a very small segment … [Katabi’s] entirely contactless sensor helps us illuminate the darkness.”

See also

About this AI and Parkinson’s disease research news

Author: Anne Trafton
Source: MIT
Contact: Anne Trafton – MIT
Image: The image is in the public domain

Original Research: Open access.
“Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals” by Yuzhe Yang et al. Nature Medicine


Abstract

Artificial intelligence-enabled detection and assessment of Parkinson’s disease using nocturnal breathing signals

There are currently no effective biomarkers for diagnosing Parkinson’s disease (PD) or tracking its progression.

Here, we developed an artificial intelligence (AI) model to detect PD and track its progression from nocturnal breathing signals. The model was evaluated on a large dataset comprising 7,671 individuals, using data from several hospitals in the United States, as well as multiple public datasets.

The AI model can detect PD with an area-under-the-curve of 0.90 and 0.85 on held-out and external test sets, respectively. The AI model can also estimate PD severity and progression in accordance with the Movement Disorder Society Unified Parkinson’s Disease Rating Scale (R = 0.94, P = 3.6 × 10–25).

The AI model uses an attention layer that allows for interpreting its predictions with respect to sleep and electroencephalogram. Moreover, the model can assess PD in the home setting in a touchless manner, by extracting breathing from radio waves that bounce off a person’s body during sleep.

Our study demonstrates the feasibility of objective, noninvasive, at-home assessment of PD, and also provides initial evidence that this AI model may be useful for risk assessment before clinical diagnosis.

Read original article here

Mystery illness that killed dozens of dogs across Michigan identified

Veterinarians have identified the disease that killed more than 20 dogs in a single Michigan shelter as parvovirus.

From the beginning, veterinarians identified that the symptoms of the previously mysterious illness matched that of parvovirus, but dogs tested negative for the virus. The Otsego County Animal Shelter initially reported it was seeing its dogs die of the disease.

“Screening tests for parvo are done to help guide immediate isolation, disinfection, and treatment protocols. While those tests are valuable in the clinical setting, they are not as sensitive as the diagnostic tests we can perform here in the laboratory,” Michigan State University’s Veterinary Diagnostic Laboratory Director Kim Dodd said in a press release. “We continue to further characterize the virus in hopes of better understanding why those animals were testing negative on screening tests.”

SEE IT: KRISPY KREME ADDS DOGGY DOUGHNUTS TO ITS MENU FOR NATIONAL DOG DAY

Hunter Venable pets his Pit Bull, Shar Pei mix Abigail while at work at Authentic Entertainment in Burbank, Calif., Monday, June 11, 2012. Abigail is one of millions of dogs that accompany their owners to dog-friendly businesses across the country every day. Even more will join her next Friday for Take Your Dog to Work Day.

(AP Photo/Grant Hindsley)

“Canine parvovirus is a severe and highly contagious disease in dogs, but MDARD and veterinary professionals have extensive experience with this virus,” State Veterinarian Nora Wineland said. “We have a highly effective vaccine available to help protect dogs from the virus. Dogs that are not fully vaccinated against this virus are the most at risk.”

The affected dogs were not fully vaccinated against the virus, according to the Michigan Department of Agriculture and Rural Development. It is not contagious to humans or other species of domestic animals.

CLICK HERE TO READ MORE FROM THE WASHINGTON EXAMINER

Symptoms of canine parvovirus include loss of appetite, bloating, fever, hypothermia, vomiting, and severe diarrhea, among others, according to the American Veterinary Medical Association.

appId : '190451957673826',

xfbml : true, version : 'v2.9' }); }; (function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));

(function(d, s, id){ var js, fjs = d.getElementsByTagName(s)[0]; if (d.getElementById(id)) {return;} js = d.createElement(s); js.id = id; js.src = "https://connect.facebook.net/en_US/sdk.js"; fjs.parentNode.insertBefore(js, fjs); }(document, 'script', 'facebook-jssdk'));

Read original article here

Diet Can Influence Mood, Behavior and More

Summary: Researchers evaluate how our choice of diet can impact our moods and behaviors, and explain how specific diets can help manage certain neurological conditions.

Source: The Conversation

During the long seafaring voyages of the 15th and 16th centuries, a period known as the Age of Discovery, sailors reported experiencing visions of sublime foods and verdant fields. The discovery that these were nothing more than hallucinations after months at sea was agonizing. Some sailors wept in longing; others threw themselves overboard.

The cure for these harrowing mirages turned out to be not a concoction of complex chemicals, as once suspected, but rather the simple antidote of lemon juice. These sailors suffered from scurvy, a disease caused by a deficiency of vitamin C, an essential micronutrient that people acquire from eating fruits and vegetables.

Vitamin C is important for the production and release of neurotransmitters, the chemical messengers of the brain. In its absence, brain cells do not communicate effectively with one another, which can lead to hallucinations.

As this famous example of early explorers illustrates, there is an intimate connection between food and the brain, one that researchers like me are working to unravel. As a scientist who studies the neuroscience of nutrition at the University of Michigan, I am primarily interested in how components of food and their breakdown products can alter the genetic instructions that control our physiology.

Beyond that, my research is also focused on understanding how food can influence our thoughts, moods and behaviors. While we can’t yet prevent or treat brain conditions with diet, researchers like me are learning a great deal about the role that nutrition plays in the everyday brain processes that make us who we are.

Perhaps not surprisingly, a delicate balance of nutrients is key for brain health: Deficiencies or excesses in vitamins, sugars, fats and amino acids can influence brain and behavior in either negative or positive ways.

Vitamins and mineral deficiencies

As with vitamin C, deficits in other vitamins and minerals can also precipitate nutritional diseases that adversely impact the brain in humans. For example, low dietary levels of vitamin B3/niacin – typically found in meat and fish – cause pellagra, a disease in which people develop dementia.

Niacin is essential to turn food into energy and building blocks, protect the genetic blueprint from environmental damage and control how much of certain gene products are made. In the absence of these critical processes, brain cells, also known as neurons, malfunction and die prematurely, leading to dementia.

In animal models, decreasing or blocking the production of niacin in the brain promotes neuronal damage and cell death. Conversely, enhancing niacin levels has been shown to mitigate the effects of neurodegenerative diseases such as Alzheimer’s, Huntington’s and Parkinson’s. Observational studies in humans suggest that sufficient levels of niacin may protect against these diseases, but the results are still inconclusive.

Interestingly, niacin deficiency caused by consumption of excessive amounts of alcohol can lead to similar effects as those found with pellagra.

Another example of how a nutrient deficiency affects brain function can be found in the element iodine, which, like niacin, must be acquired from one’s diet. Iodine, which is present in seafood and seaweed, is an essential building block for thyroid hormones – signaling molecules that are important for many aspects of human biology, including development, metabolism, appetite and sleep. Low iodine levels prevent the production of adequate amounts of thyroid hormones, impairing these essential physiological processes.

Iodine is particularly important to the developing human brain; before table salt was supplemented with this mineral in the 1920s, iodine deficiency was a major cause of cognitive disability worldwide. The introduction of iodized salt is thought to have contributed to the gradual rise in IQ scores in the past century.

Ketogenic diet for epilepsy

Not all dietary deficiencies are detrimental to the brain. In fact, studies show that people with drug-resistant epilepsy – a condition in which brain cells fire uncontrollably – can reduce the number of seizures by adopting an ultralow-carbohydrate regimen, known as a ketogenic diet, in which 80% to 90% of calories are obtained from fat.

Carbohydrates are the preferred energy source for the body. When they are not available – either because of fasting or because of a ketogenic diet – cells obtain fuel by breaking down fats into compounds called ketones. Utilization of ketones for energy leads to profound shifts in metabolism and physiology, including the levels of hormones circulating in the body, the amount of neurotransmitters produced by the brain and the types of bacteria living in the gut.

Researchers think that these diet-dependent changes, especially the higher production of brain chemicals that can quiet down neurons and decrease levels of inflammatory molecules, may play a role in the ketogenic diet’s ability to lower the number of seizures. These changes may also explain the benefits of a ketogenic state – either through diet or fasting – on cognitive function and mood.

Credit: Brainy Dose

Sugar, saturated fats and ultraprocessed foods

Excess levels of some nutrients can also have detrimental effects on the brain. In humans and animal models, elevated consumption of refined sugars and saturated fats – a combination commonly found in ultraprocessed foods – promotes eating by desensitizing the brain to the hormonal signals known to regulate satiety.

See also

What we eat matters, and having just the right amount of essential nutrients is key to our overall health. Image is in the public domain

Interestingly, a diet high in these foods also desensitizes the taste system, making animals and humans perceive food as less sweet. These sensory alterations may affect food choice as well as the reward we get from food.

For example, research shows that people’s responses to ice cream in brain areas important for taste and reward are dulled when they eat it every day for two weeks. Some researchers think this decrease in food reward signals may enhance cravings for even more fatty and sugary foods, similar to the way smokers crave cigarettes.

High-fat and processed-food diets are also associated with lower cognitive function and memory in humans and animal models as well as a higher incidence of neurodegenerative diseases. However, researchers still don’t know if these effects are due to these foods or to the weight gain and insulin resistance that develop with long-term consumption of these diets.

Time scales

This brings us to a critical aspect of the effect of diet on the brain: time. Some foods can influence brain function and behavior acutely – such as over hours or days – while others take weeks, months or even years to have an effect.

For instance, eating a slice of cake rapidly shifts the fat-burning, ketogenic metabolism of an individual with drug-resistant epilepsy into a carbohydrate-burning metabolism, increasing the risk of seizures.

In contrast, it takes weeks of sugar consumption for taste and the brain’s reward pathways to change, and months of vitamin C deficiency to develop scurvy.

Finally, when it comes to diseases like Alzheimer’s and Parkinson’s, risk is influenced by years of dietary exposures in combination with other genetic or lifestyle factors such as smoking.

In the end, the relationship between food and the brain is a bit like the delicate Goldilocks: We need not too little, not too much but just enough of each nutrient.

About this diet and psychology research news

Author: Monica Dus
Source: The Conversation
Contact: Monica Dus – The Conversation
Image: The image is in the public domain

Read original article here

Differences in Saliva Bacteria of Students With Recent Suicidal Thoughts

Summary: Students who reported recent suicidal thoughts had different bacterial compositions in their saliva compared to those who did not report suicidal thoughts. Significantly, suicidal students presented with lower levels of Alloprevotella rava, a bacteria associated with positive brain health, in their saliva samples.

Source: University of Florida

A new University of Florida study has found that bacteria in the saliva of college students who reported recent thoughts of suicide differed in significant ways from those found in students who had not experienced recent suicidal thinking.

While there is a growing body of research on mental health and the human microbiome, this is the first study to look at bacterial differences in the saliva of those with and without recent suicidal thoughts, also called suicidal ideation. Recent suicidal ideation was defined as thoughts of suicide within the two weeks before the saliva sample was taken.

Controlling for the influence of other factors known to impact mental health, such as diet and sleep, the researchers found that students with recent suicidal thoughts had higher levels of bacteria associated with periodontal disease and other inflammatory health conditions.

They also found that these students had lower levels of Alloprevotella rava, a bacterium known to produce a compound that promotes brain health. These students also shared a genetic variation that the researchers found may influence the presence of Alloprevotella rava in the mouth.

“These results are exciting because they tell us which bacteria we need to look at more closely. Our question now is, what are these bacteria doing biologically that affects mental health?” said Angelica Ahrens, first author of the study and a postdoctoral researcher in the UF/IFAS microbiology and cell science department. Ahrens led the study as part of her doctoral program in the UF/IFAS College of Agricultural and Life Sciences.

“Eventually, we hope this line of research could help predict suicidal ideation based on a person’s microbiome and could inform pro- or prebiotic treatments for those at risk,” said Ahrens.

The study analyzed saliva collected from nearly 500 undergraduate students taking classes in the microbiology and cell science department at UF. These students also completed the Patient Health Questionnaire-9, which is used to screen for depression symptoms and asks respondents to share if they have had thoughts of suicide within the last two weeks. Those who reported recent suicidal ideation were referred to on-campus mental health services.

“Mental health and suicide are serious issues on college campuses, and our students were very interested in being a part of research that can help address this problem. We are continuing to collect data for follow-up studies and hope more students and universities will become involved,” said Eric Triplett, chair of the microbiology and cell science department and senior author of the study.

They also found that these students had lower levels of Alloprevotella rava, a bacterium known to produce a compound that promotes brain health. Image is in the public domain

Depression and suicidal ideation are relatively common among college-aged adults: A 2020 study by the CDC found that up to a quarter of people between ages 18 to 24 had seriously thought about suicide within the last month.

For this initial study, students came to the lab to provide a saliva sample, but today participants can opt to send in their saliva sample by mail using a collection kit developed by the researchers.

“This at-home method is very convenient for students and also helps us build a more diverse dataset and test different variables. For example, we would like to look at the saliva microbiome of people who have been diagnosed with depression and are taking antidepressants,” Ahrens said.

“While various treatments and lifestyle changes can help, there is still much to be learned about how the human microbiome affects mental health and could be harnessed to improve it,” Ahrens said.

About this microbiome and mental health research news

Author: Press Office
Source: University of Florida
Contact: Press Office – University of Florida
Image: The image is in the public domain

See also

Original Research: Open access.
“Saliva microbiome, dietary, and genetic markers are associated with suicidal ideation in university students” by Angelica P. Ahrens et al. Scientific Reports


Abstract

Saliva microbiome, dietary, and genetic markers are associated with suicidal ideation in university students

Here, salivary microbiota and major histocompatibility complex (MHC) human leukocyte antigen (HLA) alleles were compared between 47 (12.6%) young adults with recent suicidal ideation (SI) and 325 (87.4%) controls without recent SI. Several bacterial taxa were correlated with SI after controlling for sleep issues, diet, and genetics.

Four MHC class II alleles were protective for SI including DRB1*04, which was absent in every subject with SI while present in 21.7% of controls. Increased incidence of SI was observed with four other MHC class II alleles and two MHC class I alleles.

Associations between these HLA alleles and salivary bacteria were also identified. Furthermore, rs10437629, previously associated with attempted suicide, was correlated here with SI and the absence of Alloprevotella rava, a producer of an organic acid known to promote brain energy homeostasis.

Hence, microbial-genetic associations may be important players in the diathesis-stress model for suicidal behaviors.

Read original article here

More polio virus detected in upstate New York wastewater

ALBANY, N.Y. (AP) — State health officials in New York are warning of expanding “community spread” of the polio virus after it was found in wastewater samples from another upstate county.

The state Department of Health said Friday the polio virus was detected in four samples from Sullivan County, two each in July and August. Sullivan County is several dozen miles northwest of Rockland County, where officials on July 21 announced the first case of polio in the United States in nearly a decade. The unidentified young adult was unvaccinated.

The Sullivan County samples are genetically-linked to the case of paralytic polio in Rockland County.

State Health Commissioner Dr. Mary T. Bassett again urged residents to make sure they are immunized, saying “one New Yorker paralyzed by polio is already too many.”

“The polio in New York today is an imminent threat to all adults and children who are unvaccinated or not up to date with their polio immunizations,” Bassett said in a prepared release.

The virus has now been identified in wastewater samples in three contiguous counties north of New York City: Rockland, Orange and Sullivan. The polio virus also has been found in New York City sewage.

Officials have said that it is possible that hundreds of people in the state have gotten polio and don’t know it. Most people infected with polio have no symptoms but can still give the virus to others for days or weeks.

Polio was once one of the nation’s most feared diseases, with annual outbreaks causing thousands of cases of paralysis. The disease mostly affects children.

Read original article here